Nasdaq · Healthcare

CRESCENT BIOPHARMA, INC. (CBIO)

As-reported financials and recent SEC filings for CRESCENT BIOPHARMA, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$10.8M

Net income

$-153.9M

Net margin

—

Diluted EPS

—

ROE

-75.8%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$10.8M	—	$10,000	$75,000	$1.2M
Gross profit	—	—	—	—	—
Operating income	$-152.6M	$-40.0M	$-39.3M	$-47.4M	$-63.4M
Net income	$-153.9M	$-37.9M	$-36.9M	$-46.7M	$-63.4M
Diluted EPS	—	$-0.59	$-0.58	$-0.89	$-1.23

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

S-32026-07-01

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CBIO

Search CRESCENT BIOPHARMA, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.